Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China
@article{TLCR78148,
author = {Qiuyan Zhu and Ronghua Ni and Xin Guan},
title = {Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China},
journal = {Translational Lung Cancer Research},
volume = {12},
number = {8},
year = {2023},
keywords = {},
abstract = {},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/78148}
}